求助来那替尼上市信息?Puma Biotechnology, under license from Pfizer (previously Wyeth), is developing neratinib (PB-272; HKI-272), an irreversible pan-HER (Erbb1, ErbB2 and ErbB4) tyrosine kinase inhibitor, for the potential oral treatment of HER2-positive cancers, primarily breast cancer In July 2009, worldwide phase III breast cancer trials were initiated by Wyeth in patients who had received prior trastuzumab-based therapy ; in October 2011, following its acquisition of rights, Puma intended to terminate the ongoing Pfizer-sponsored trials , and the company began its own phase III trial in third-line metastatic breast cancer in June 2013 . In July 2014, Puma planned to file the drug for approval in the extended adjuvant setting for breast cancer in 1H15 . Development in other HER2-positive cancer settings is ongoing. In April 2013, a phase II trial in patients with NSCLC was ongoing . In October 2013, a phase II study in patients with other solid tumors with a HER2 mutation was initiated ; in March 2014, initial data from the trial were expected in 2014查看更多
第1天
关注盖德视界
添加小助手
